• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Scientists Urge NIH to Consider Human Challenge Trials for COVID-19 Vaccine

Scientists Urge NIH to Consider Human Challenge Trials for COVID-19 Vaccine

July 20, 2020

In an open letter to the National Institutes of Health (NIH), more than 125 of the world’s top scientists have called on the U.S. government to start conducting human challenge trials to accelerate COVID-19 vaccine development.

Citing the urgency of finding a vaccine for the deadly virus, the scientists — among them 15 Nobel laureates as well as the director of Oxford University’s large COVID-19 vaccine program — say the ethical objections to infecting healthy volunteers with a disease that has no known cure are outweighed by the common good.

In a similar letter sent to the FDA in April, 35 U.S. lawmakers also encouraged the use of challenge trials, saying “justifiable risks may be taken” (CenterWatch Weekly, April 27). The agency responded by suggesting animal testing could be used instead.

NIH Director Francis Collins’ previously stated position on the subject has been that challenge trials are open to discussion, but that NIH is not yet ready to move forward with a human challenge trial plan.

Earlier this month, members of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) working group wrote in an article in the New England Journal of Medicine that deliberately infecting healthy individuals without a life-saving treatment on hand would be unethical. ACTIV members expressed support for traditional randomized controlled trials of SARS-CoV-2 vaccines as the most efficient path to a vaccine.

The July 15 letter to the NIH was published on the website of 1 Day Sooner, a nonprofit organization that has recruited more than 32,000 healthy volunteers in 140 countries who are willing to participate in challenge trials.

To read the letter, click here: https://bit.ly/2CKSFBD.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing